David Katz

|RSS

David Katz is the president and chief investment officer of Matrix Asset Advisors, which he co-founded in 1986. Prior to co-founding Matrix, he worked at Management Asset Corp. in the research and portfolio management areas. At Matrix, Katz chairs the Investment Policy Committee.Expand

Katz is a CFA charterholder who appears frequently as a guest on CNBC, Bloomberg Television and Radio and WCBS-AM in New York. He graduated summa cum laude from Union College with a Bachelor of Arts degree in economics. He received a Master of Business Administration degree, with a concentration in finance, from New York University Graduate School of Business in 1987, graduating with distinction. His numerous works on value investing earned him various awards and distinctions at the undergraduate and graduate levels.Collapse

By

David Katz

 | Jan 13, 2017 | 9:00 AM EST
The company's margins and cash flows are unbelievably attractive.
By

David Katz

 | Jan 11, 2017 | 3:26 PM EST
While it's going to be a long year with headline risk (political and otherwise) for the drug companies, we do think they represent one of the more...
By

David Katz

 | Jan 11, 2017 | 8:00 AM EST
This pharma company is still making lots of money and its stock is too cheap to pass up.
By

David Katz

 | Jan 10, 2017 | 2:16 PM EST
Investors were not expecting a lot from Zimmer Biomet's (ZBH) CEO at JP Morgan Healthcare investor conference today. Investors were still reeling...
By

David Katz

 | Jan 10, 2017 | 1:36 PM EST
This morning, Larry Merlo, CEO of CVS Health, gave a presentation at the J.P. Morgan Health Care conference and reiterated the company's value...
RMPIA
By

David Katz

 | Jan 8, 2017 | 2:00 PM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

David Katz

 | Jan 6, 2017 | 7:00 AM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

David Katz

 | Jan 5, 2017 | 10:00 AM EST
Shares are dirt cheap as revenues and profits have grown.
By

David Katz

 | Jan 4, 2017 | 10:00 AM EST
None of these 10 stocks finished the year in the red.
By

David Katz

 | Dec 30, 2016 | 1:44 PM EST
While there is as good a chance as not that there might be some first week selling of some of 2016's winners, we also think that some of the years...

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.